19 results on '"Kahl, Christoph"'
Search Results
2. PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study
3. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
4. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
5. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
6. Radiation dose determines the degree of myeloid engraftment after nonmyeloablative stem cell transplantation
7. Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)
8. Response-Adapted Sequential Treatment with Azacitidine and Intensive Chemotherapy in Patients > 60 Years Old with Newly Diagnosed AML: Results of the RAS-Azic Trial of the East German Study Group (OSHO)
9. Prognostic Factors for Overall Survival in Relapsed Acute Myeloid Leukemia
10. Long Term Follow up of the AML97-Study for Patients with AML Older Than 60 Years: A Study of the East German Hematology and Oncology Study Group (OSHO)
11. Increasing The Dose Of AraC In Consolidation Therapy Does Not Lead To Higher Overall Survival Or Improved Relapse Incidence In Patients With AML Over The Age Of 60 Years
12. Conditioning with Treosulfan and Fludarabine for Patients with Refractory or Relapsed Non-Hodgkin Lymphoma (NHL),
13. Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).
14. Incidence and Outcome of Non-CMV Viral Infections in 202 Consecutive Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipients.
15. Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.
16. Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.
17. Nonmyeloablative and Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies: Outcomes with HLA-Matched Unrelated Donors Compared to HLA-Identical Sibling Donors.
18. Radiation Dose Determines Degree of Donor Chimerism after Nonmyeloablative Hematopoietic Cell Transplantation.
19. Marrow Allografts after Nonmyeloablative Conditioning: Effect of Cell Dose on Rejection and Degree of Donor Chimerism.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.